James Sanders

James Sanders

Auto-generated profile, based on publicly available information

James Sanders

Department of Pharmacy, University of Texas Southwestern Medical Center , Dallas, Texas

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
KCKaylee E Caniff
Kaylee E Caniff
NRNicholas Rebold
Nicholas Rebold
XXXhilda Xhemali
Xhilda Xhemali
NTNikki Tran
Nikki Tran
TETaryn Ashley Eubank
Taryn Ashley Eubank
MRMichael J. Rybak
Michael J. Rybak
Background: Multidrug-resistant (MDR) gram-negative infections are a substantial threat to patients and public health. Imipenem-cilastatin-relebactam (IMI/REL) is a β-lactam/β-lactamase inhibitor with expanded activity against MDR Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. This study aims to describe the patient characteristics, prescribing patterns, and clinical outcomes associated with IMI/REL. Methods: This was a retrospective, multicenter, observational study of patients ≥18 years old who received IMI/REL for ≥48 hours for a suspected or confirmed gram-negative infection. The primary outcome was clinical success, defined as improvement or resolution of infection-related signs or symptoms while receiving IMI/REL and the absence of 30-day microbiologic failure. Multivariable logistic regression analysis was performed to identify independent predictors of clinical success. Results: The study included 151 patients from 24 US medical centers. IMI/REL was predominantly prescribed for lower respiratory tract infections, accounting for 52.3% of cases. Most patients were infected with a carbapenem-nonsusceptible pathogen (85.4%); P aeruginosa was frequently targeted (72.2%). Clinical success was achieved in 70.2% of patients. Heart failure, receipt of antibiotics within the past 90 days, intensive care unit admission at time of index culture collection, and isolation of difficult-to-treat resistant P aeruginosa were independently associated with a reduced odds of clinical success. Adverse events were reported in 6.0% of patients, leading to discontinuation of IMI/REL in 3 instances. Conclusions: This study provides a comprehensive analysis of the real-world effectiveness and safety of IMI/REL. Comparative studies and investigations of specific subgroups will further enhance our understanding of IMI/REL in treating MDR infections.

3 March 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
MMMarguerite L Monogue
Marguerite L Monogue
JSJames M Sanders
James M Sanders
NMNicholas J Mercuro
Nicholas J Mercuro
CHCrystal K Hodge
Crystal K Hodge
EGEsther Golnabi
Esther Golnabi
JCJames B Cutrell
James B Cutrell
Pharmacokinetic (PK) and pharmacodynamic (PD) variability in special populations can impact antimicrobial efficacy and safety. This review highlights the importance of PK/PD optimization in patients known to have altered PK, including those with obesity, cystic fibrosis, renal dysfunction, critical illness, transplantation, pregnancy, and/or significant burns. Historically, PK/PD data are underrepresented in these populations, leading to suboptimal dosing recommendations and increased risks of therapeutic failure or toxicity. Herein, we discuss key physiological alterations affecting antimicrobial PK/PD, regulatory challenges, and currently available solutions. To bridge these knowledge gaps, we advocate for broader patient inclusion in clinical trials, improved PK modeling, real-world data collection, and increased investment in precision dosing strategies. Addressing these issues has the potential to enhance patient outcomes, reduce antimicrobial resistance, and improve infectious diseases management. This review serves as a call to action for researchers, clinicians, and policymakers to prioritize PK/PD research in special patient populations.

15 February 2026 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
JBJeannette Bouchard
Jeannette Bouchard
Spencer DurhamSpencer Durham
Spencer Durham
AKAmy Y. Kang
Amy Y. Kang
KJKinsey M. Johannemann
Kinsey M. Johannemann
ECElizabeth Covington
Elizabeth Covington

1 October 2021 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JCJames B Cutrell
James B Cutrell
JSJames M Sanders
James M Sanders
James B Cutrell, MD, James M Sanders, PhD, PharmD; “The Early Beta-lactam Catches the Germ”: Empiric Antimicrobial Sequence in Bloodstream Infections, Clinical

4 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJames Sanders
James Sanders
MMMarguerite Monogue
Marguerite Monogue
DGDavid E. Greenberg
David E. Greenberg
CPChristine A Pybus
Christine A Pybus
ACAndrew E Clark
Andrew E Clark
Cystic fibrosis (CF) patients are often colonized with Pseudomonas aeruginosa (PSA). During treatment, PSA can develop subpopulations exhibiting variable in vitro antimicrobial susceptibility patterns. Heteroresistance may underlie the reported discordant in vitro results and clinical responses to various antimicrobials. Here, we sought to examine the presence and nature of PSA heteroresistance to ceftolozane-tazobactam (C-T) in isolates originating from CF pulmonary exacerbations. Respiratory cultures from 26 adult CF patients were collected. From each sample, 5-10 PSA colonies were selected. Susceptibility testing was conducted via E-test for C-T, ceftazidime-avibactam (CZA), and imipenem-relebactam (I-R). Polyclonal-heteroresistance (PHR) was defined as the presence of different susceptibility profiles among the colonies that originated from a single patient specimen. Population analysis profile (PAPs) were performed to assess the presence of monoclonal-heteroresistance (MHR), defined as ≥ 4 fold change in the C-T MIC from a single colony over 24-48 hours. 246 PSA isolates from 26 adult CF patients were included. The C-T MIC50 and MIC90 were 1/4 and ≥ 256/4 µg/mL, respectively (Figure 1). Sixteen of the 26 patients (62%) demonstrated ≥ 2 fold change in C-T MIC between isolates from the same culture. Of these 16 isolates, the fold change in C-T MIC was >2 fold for 7 isolates (27%) and resulted in a susceptibility interpretation change in 6 of the isolates (23%). Of the 32 isolates that underwent PAP testing, 7 grew on MH plates at 2-fold the C-T MIC concentration. One isolate, PSA 1311, demonstrated growth on PAPs up to 4 fold the MIC (16/4 µg/mL) (Figure 2). Figure 1. Ceftolozane-tazobactam, ceftazidime-avibactam, and imipenem-relebactam MIC distributions against PSA isolates from 26 adult CF patients Figure 2. Monoclonal heteroresistance to C-T (PSA 1311 [C-T MIC 1/4 µg/mL] PAPs at 2, 4, 6, and 8-fold the C-T MIC). Susceptibilities to C-T and CZA were similar across our CF PSA isolates. Comparatively, I-R retained better in vitro potency. C-T PHR exists among PSA isolates in the majority of our CF patients. Approximately 25% of these PHR isolates resulted in susceptibility interpretation changes supporting concerns surrounding the utility of traditional susceptibility testing methodology for CF isolates. These data suggest MHR also exists, albeit rare in this small subset. Additional data are needed to better understand these results in clinical context. David E. Greenberg, MD, Shionogi (Grant/Research Support)Solenic Medical (Shareholder)

1 January 2025 in Pulmonary Medicine
Verified
Journal Article
Open access
DSDarrell Smith
Darrell Smith
JSJames Sanders
James Sanders
MMMarguerite Monogue
Marguerite Monogue
Background: Therapeutic drug monitoring (TDM) for vancomycin (VAN) in adult people with cystic fibrosis (pwCF) historically has utilized trough concentrations. Recent VAN TDM guidelines recommend area under the curve (AUC) monitoring to reduce the risk of acute kidney injury (AKI), despite limited evidence to support this practice in adult pwCF. Methods: This single‐center, retrospective, observational cohort study included 143 adult pwCF admitted from July 1, 2017, to July 1, 2022, with an acute pulmonary exacerbation that received VAN for at least 72 h with available VAN plasma concentrations for TDM for AUC ( n = 39) or trough monitoring ( n = 104). Eligible patients with multiple hospital admissions during the study period were incorporated as separate encounters. The primary outcome was the incidence of AKI. Results: Receipt of concurrent nephrotoxins was more common in the AUC cohort than in the trough cohort (97% vs. 81%, p = 0.01), but the rate of AKI was similar (7.7% vs. 10.6%, p = 0.76). AUC monitoring was associated with earlier achievement of TDM goal (median 0 days (IQR 0–2) vs. 2 days (IQR 0–4), p < 0.01), lower total daily doses (34.8 mg/kg/day (IQR 27.6–49) vs. 57.5 mg/kg/day (IQR 43.9–68.6), p < 0.01), and fewer regimen changes (median 1 change (IQR 0–2) vs. 2 changes (IQR 1–3), p < 0.01). In patients with MRSA, pulmonary function recovery, readmission, and mortality were similar. Conclusion: In adult pwCF, the incidence of AKI was similar between AUC and trough monitoring cohorts; however, AUC monitoring achieved therapeutic targets sooner with fewer regimen modifications without significantly increasing the number of concentrations compared to trough monitoring.